Gendelman et al. conducted a placebo-controlled double-blind phase 1 trial and found that sargramostim, a granulocyte–macrophage colony-stimulating factor (GM-CSF), could improve PD in comparison to the placebo [250]. Here, CSF2 is linked to Parkinson disease.